207 related articles for article (PubMed ID: 29074274)
1. Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development.
Radi ZA; Vogel WM; Bartholomew PM; Koza-Taylor P; Papanikolaou A; Wisialowski T; Nambiar P; Ball DJ
Regul Toxicol Pharmacol; 2017 Dec; 91():93-102. PubMed ID: 29074274
[TBL] [Abstract][Full Text] [Related]
2. Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
Radi Z; Bartholomew P; Elwell M; Vogel WM
Toxicol Appl Pharmacol; 2013 Dec; 273(3):456-63. PubMed ID: 24141031
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Chapin RE; Ball DJ; Radi ZA; Kumpf SW; Koza-Taylor PH; Potter DM; Mark Vogel W
Toxicol Sci; 2017 Jan; 155(1):148-156. PubMed ID: 27708194
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
5. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
8. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
10. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
12. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
14. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological effects of nicotine on norepinephrine metabolism in rat brown adipose tissue: relevance to nicotinic therapies for smoking cessation.
Brees DJ; Elwell MR; Tingley FD; Sands SB; Jakowski AB; Shen AC; Cai JH; Finkelstein MB
Toxicol Pathol; 2008 Jun; 36(4):568-75. PubMed ID: 18467676
[TBL] [Abstract][Full Text] [Related]
16. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.
Chikugo M; Sebe M; Tsutsumi R; Iuchi M; KIshi J; Kuroda M; Harada N; Nishioka Y; Sakaue H
J Med Invest; 2018; 65(3.4):166-170. PubMed ID: 30282855
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
18. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ; Bukowski JF; Brennan TV; Noveck RJ; Staats JS; Lin L; Stempora L; Hammond C; Wouters A; Mojcik CF; Cheng J; Collinge M; Jesson MI; Hazra A; Biswas P; Lan S; Clark JD; Hodge JA
Clin Immunol; 2018 Jun; 191():10-20. PubMed ID: 29518577
[TBL] [Abstract][Full Text] [Related]
19. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Boor PPC; de Ruiter PE; Asmawidjaja PS; Lubberts E; van der Laan LJW; Kwekkeboom J
Transl Res; 2017 Oct; 188():67-79. PubMed ID: 27931982
[TBL] [Abstract][Full Text] [Related]
20. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
